Department of Dermatology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA.
Int J Dermatol. 2010 Oct;49(10):1203-6. doi: 10.1111/j.1365-4632.2010.04606.x.
Sorafenib and sunitinib, novel anti-tumor agents approved for the treatment of renal cell carcinoma, have been associated with multiple adverse cutaneous effects.
To further investigate the constellation of possible adverse effects of sorafenib and sunitinib on the skin.
Case report of a 62 year old male with history of renal cell carcinoma treated with adjuvant sorafenib.
Our patient experienced a diffuse hyperkeratotic rash, hand-foot skin reaction, facial erythema, and stomatitis within three weeks of initiation of sorafenib.
Further investigation regarding the possible adverse cutaneous effects of sorafenib and sunitinib, pathogenesis and risk factors for development, associated time course, and preventative and therapeutic methods, will allow for better patient and physician education.
索拉非尼和舒尼替尼是两种新型抗肿瘤药物，已被批准用于治疗肾细胞癌，它们与多种皮肤不良反应相关。
进一步研究索拉非尼和舒尼替尼对皮肤可能产生的不良反应。
报道 1 例 62 岁男性肾细胞癌患者，接受辅助索拉非尼治疗。
我们的患者在开始使用索拉非尼 3 周内出现弥漫性角化过度性皮疹、手足皮肤反应、面部红斑和口腔炎。
进一步研究索拉非尼和舒尼替尼可能的皮肤不良反应、发病机制和危险因素、相关时间进程以及预防和治疗方法，将有助于更好地对患者和医生进行教育。
Zotero 插件